Johnson & Johnson (JNJ)
| Market Cap | 472.05B |
| Revenue (ttm) | 92.15B |
| Net Income (ttm) | 25.12B |
| Shares Out | 2.41B |
| EPS (ttm) | 10.35 |
| PE Ratio | 18.93 |
| Forward PE | 17.57 |
| Dividend | $5.20 (2.65%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 8,824,847 |
| Open | 195.00 |
| Previous Close | 195.25 |
| Day's Range | 193.55 - 197.18 |
| 52-Week Range | 140.68 - 197.18 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 196.19 (+0.13%) |
| Earnings Date | Oct 14, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $196.19, which is an increase of 0.13% from the latest price.
News
Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion
Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant's oncology pipeline.
Halda Therapeutics Announces Acquisition by Johnson & Johnson
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05 ...
J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion
Johnson & Johnson said on Monday it would buy Halda Therapeutics for $3.05 billion in cash, expanding its presence in solid tumors and prostate cancer treatments.
New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety prof...
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage b...
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Bristol Myers, J&J halt heart drug trial after interim review
Bristol Myers Squibb and Johnson & Johnson said on Friday they would stop a late-stage trial of their experimental blood clot drug in heart attack patients, after an independent review found the study...
Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript
Johnson & Johnson ( JNJ) UBS Global Healthcare Conference 2025 November 11, 2025 11:00 AM EST Company Participants Peter Menziuso Conference Call Participants Danielle Antalffy - UBS Investment Bank,...
Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Johnson & Johnson ( JNJ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 10:30 AM EST Company Participants Sarah Brennan Mark Wildgust Conference Call Participants...
Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating
Johnson & Johnson remains a "buy" following strong Q3 2025 results, driven by robust sales growth and raised full-year 2025 revenue guidance. The company's acquisition of Intra-Cellular Therapies and ...
FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression
The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson's (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.
Johnson & Johnson: Dividends Don't Lie
Johnson & Johnson's latest dividend declaration translates into an annual growth rate of 4.47%. This is the lowest level in at least 10 years, signaling ongoing growth pressures. Mixed Q3 earnings res...
DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Landmark approval supports ...
Cramer's Mad Dash: Johnson & Johnson
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
US FDA expands use of J&J's Caplyta as add-on depression drug
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said on Thursday.
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications1,2 In pivotal trials, CAP...
Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Citi's 2025 Global Healthcare Conference on Wednesday, December 3rd, 2025. Management will participate in a Fire...
Best Dividend Aristocrats For November 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW...
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG stud...
Best Dividend Kings: October 2025
Dividend Kings are underperforming SPY in 2025, with a year-to-date return gap of 13.10%, but 12 Kings remain ahead of the index. Top performers include NFG, JNJ, ABBV, MO, FTS, ADM, NUE, GRC, NWN, PH...
Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson
FORT LAUDERDALE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- A jury today awarded $20 million to the family of Dr. Alberto A.
J&J Stock Can Fall
Johnson & Johnson (JNJ) is currently encountering challenges. Even the largest corporations are not invulnerable.
Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks
The makers of Tylenol, Johnson & Johnson and Kenvue , were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug's links to autism and attention deficit h...
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
Findings highlight opportunity for shared decision-making to improve treatment planning, with more than 90% of patients currently on injectables willing to switch to a new oral therapy with equivalent...
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies TREMFYA® is the only IL-23 inhibitor to demonstrate durable endosc...